Background: The B-cell receptor transmembrane activator and calcium modulator ligand interactor (TACI) is important for T-independent antibody responses. One in 200 blood donors are heterozygous for the TACI A181E mutation. Objective: We sought to investigate the effect on B-cell function of TACI A181E heterozygosity in reportedly healthy subjects and of the corresponding TACI A144E mutation in mice. Methods: Nuclear factor kB (NF-kB) activation was measured by using the luciferase assay in 293T cells cotransfected with wild-type and mutant TACI. TACI-driven proliferation, isotype switching, and antibody responses were measured in B cells from heterozygous TACI A144E knock-in mice. Mouse mortality was monitored after intranasal pneumococcal challenge. Results: Levels of natural antibodies to the pneumococcal polysaccharide component phosphocholine were significantly lower in A181E-heterozygous than TACI-sufficient Swedish blood donors never immunized with pneumococcal antigens. Although overexpressed hTACI A181E and mTACI A144E acted as dominant-negative mutations in transfectants,
The transmembrane activator and calcium modulator ligand interactor (TACI) is a TNF receptor (TNFR) superfamily member expressed on B cells. 1 The TNF family members B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are ligands for TACI. [2] [3] [4] The extracellular region of TACI contains 2 cysteine-rich domains (CRDs). Ligand binding causes clustering of the intracellular domains of TACI, recruitment of signaling molecules that include calcium modulator ligand and TNFRassociated factor proteins, and activation of the transcription factors nuclear factor of activated T cells and nuclear factor kB (NF-kB). 1, [5] [6] [7] TACI is important in immunoglobulin class-switching, immunoglobulin production, regulation of B-cell homeostasis, and the antibody response to type II T-independent (TI) antigens, which include natural antibodies to bacterial antigens and the pneumococcal polysaccharide component phosphocholine. 5, [8] [9] [10] TNFRSF13B, which encodes TACI, is mutated in up to 10% of patients with common variable immunodeficiency (CVID). 8, 11, 12 Most (90%) of these patients are heterozygous for the TACI C104R or A181E mutations. The C104R mutation, which is located in the second CRD, abolishes ligand binding. 8, 11 The A181E mutation, which is located in the transmembrane domain, does not affect ligand binding but severely impairs ligandinduced signaling. 13 B cells from patients with CVID with heterozygous C104R and A181E mutations in TACI have impaired response to TACI ligation in vitro. 8, 11 About 1 in 200 of reportedly healthy subjects are heterozygous for the A181E mutation (Exome Aggregation Consortium . Thus the A181E mutation is not a cause of CVID but a risk factor and modifier for the disease. The effect of TACI A181E heterozygosity on B-cell function in these subjects is not known. Herein we show that the levels of natural antibodies to phosphocholine in apparently healthy adults subjects never immunized with pneumococcal antigens are significantly lower in A181E heterozygotes compared with those in TACIsufficient control subjects. Because human subjects have complex heterogeneous genetic backgrounds, we investigated the effect of an isolated A144E mutation in mice, which corresponds to the A181E mutation in human subjects, on the immune response to TI type II antigens to determine the mechanistic basis of the impaired anti-phosphocholine response in apparently healthy A181E carriers with no CVID. We demonstrate that heterozygosity for mTACI A144E causes TACI haploinsufficiency and increased susceptibility to pneumococcal infection.
METHODS

Human studies
Sera from 14 TACI A181E heterozygotes and 20 TACI-sufficient control subjects were derived from a pool of 1730 reportedly healthy Swedish adult blood donors previously analyzed for TACI mutations. 11 Samples were anonymized, and no ethical permit was needed according to Swedish rules. Serum IgM-specific (at 1:100 dilution) and IgG-specific (at 1:500 dilution) antibodies to phosphocholine were measured by means of ELISA, as described below. For IgG anti-phosphocholine affinity measurement, because of the small volume of sera available, we pooled equal-volume aliquots of sera from A181E carriers and TACI-sufficient Swedish blood donors, respectively. After serum (diluted at 1:100) incubation for 2 hours, ELISA plates were washed, and then sodium thiocyanate diluted in water at 2, 1, 0.5, or 0.25 mol/L was added for 30 minutes. The anti-phosphocholine IgG ELISA assay was run in triplicate, and the mean 6 SEM percentage inhibition of binding was determined based on the OD reading of the sample treated with water alone. The sodium thiocyanate molarity that resulted in 50% binding inhibition was determined from the fitted inhibition curve. IgM antibodies to Escherichia coli were measured by means of ELISA with 0.5% formalin-fixed E coli cells (New England Biolabs, Ipswich, Mass) for capturing and alkaline phosphatase-conjugated goat anti-human IgM for detection. Anti-tetanus (tetanus toxoid) IgG levels were measured by using an ELISA, according to the manufacturer's instructions (IBL International, Morrisville, NC).
Generation of TACI A144E KI mice
The strategy for the construction of the targeting vector is outlined in Fig E1 in this article's Online Repository at www.jacionline.org. Embryonic stem cell clones were generated by using standard methods. Two correctly targeted embryonic stem cell clones were identified and injected into 3.5-day-old C57BL/6 blastocysts (see Fig E1, A) to generate mice that carry a Tnfrsf13b mutated allele encoding mTACI A144E. The floxed neo cassette was removed by breeding with BALB/c mice expressing Cre recombinase under the control of the cytomegalovirus promoter (#003465; Jackson Laboratories, Bar Harbor, Me). Founders identified by means of PCR analysis of genomic DNA were appropriately crossed to generate the desired strains. All mice were bred for more than 10 generations on the C57BL/6 background. Mouse studies were performed in accordance with Boston Children's Hospital's policies and procedures.
RT-PCR and quantitative PCR analysis of Tnfrsf13b mRNA levels
Genotyping of mice was performed by means of RT-PCR of tail genomic DNA with the forward primer 59-AGGTTCAAGTCGCAAGCTGT-39 and the reverse primer 59-CCCCTGGGTGAGCTTAGACT-39. For Tnfrsf13b mRNA expression, RNA was extracted from purified spleen B cells by using TRIzol (Invitrogen, Carlsbad, Calif) and reverse transcribed by using Superscript II RT (Invitrogen). Quantitative PCR was performed with primers and the ABI Prism 7300 sequence detector from Applied Biosystems (Foster City, Calif). Relative mRNA expression normalized to b 2 -microglobulin was calculated by using the relative standard curve method (Applied Biosystems).
Flow cytometry
Single-cell suspensions were stained with the appropriate fluorochromelabeled antibodies in the presence of Fc Block (BD PharMingen, San Jose, Calif) and analyzed on an LSRFortessa cell analyzer (BD Biosciences). Data collected were analyzed with FlowJo software (TreeStar, Ashland, Ore). Fluorescence-labeled mAbs to B220 (RA3-6B2), CD3e (145-2C11), and CD43 (S7) were purchased from BD PharMingen; those to CD4 (GK1.5), CD16/CD32 (93), CD21/35 (8D9), CD23 (B3B4), CD24 (M1/69), CD5 (53-7.3), CD11b (M1/70), and IgM (11/41) were purchased from eBioscience (San Diego, Calif); and that to TACI was purchased from R&D Systems (Minneapolis, Minn). Intracellular staining was done per the instructions provided with the Cytofix/Cytoperm kit (BD Biosciences).
Immunizations
Mice 8 to 12 weeks of age were used. For type II TI immunizations, mice received a single intraperitoneal injection of TNP-Ficoll (25 mg per mouse; TNP(83)-AECM-Ficoll; Biosearch Technologies, Petaluma, Calif). On days 0 and 14, serum was collected for measurement of TNP-specific immunoglobulin production. For 4-hydroxy-3-nitrophenyl acetyl-ovalbumin (NP-OVA) immunization, mice received 100 mg of NP-OVA intraperitoneally on day 0. 14 
Serum immunoglobulin and antibody measurements
Serum immunoglobulin levels were measured by means of ELISA, as previously described. 15 TNP-, NP-, and phosphocholine-specific antibodies were measured by means of ELISA with plates coated with 10 mg/mL TNP, NP, and phosphocholine conjugated to BSA (Biosearch Technologies), respectively.
In vitro immunoglobulin synthesis and proliferation of B cells were performed, as previously described. 13 Challenge of mice with Streptococcus pneumoniae type 3 strain
Data analysis
Statistical analysis of the data using the Student 2-tailed t test, 2-way ANOVA, and the log-rank (Mantel-Cox) test was performed with Prism 4.0a software (GraphPad Software).
For additional methods, see the Methods section in this article's Online Repository www.jacionline.org.
RESULTS
Asymptomatic human carriers of the TACI A181E mutation have impaired natural antibody responses
Antibodies to phosphocholine, which is present on all S pneumoniae strains as part of the cell-wall polysaccharide, 17, 18 are thought to protect against invasive pneumococcal disease in human subjects. 19 Phosphocholine antibodies were measured in sera from 14 A181E heterozygotes and 20 TACI-sufficient Swedish blood donors who had never been vaccinated with pneumococcal antigens because pneumococcal vaccination was not performed in Sweden for their age group. Serum levels of natural IgM and IgG antibodies to phosphocholine were significantly lower in the A181E heterozygotes compared with control subjects (Fig 1, A) . However, the affinity of antiphosphocholine IgG antibodies was significantly higher in A181E heterozygotes compared with control subjects (Fig 1,  B) . Serum levels of natural IgM antibodies to E coli were also significantly lower in the A181E heterozygotes compared with control subjects (Fig 1, C) . Serum levels of IgM, IgG, and IgA of antibodies to the T-dependent (TD) antigen tetanus toxoid were not significantly different between the 2 groups (Fig 1, D , and data not shown). These results indicate that the heterozygous A181E mutation impairs the natural antibody response to TI bacterial antigens in reportedly healthy human subjects.
Phenotypic analysis of lymphocytes in TACI A144E knock-in mice TNF family ligands transduce signals though inducing clustering of the intracellular domain of their receptors, and most TNFRs also have some degree of preligand association, which is thought to facilitate signaling. 20, 21 We examined whether hTACI A181E and mTACI A144E could assemble with their wild-type (WT) counterparts. Flag-tagged mutants and their Myc-tagged WT counterparts were cotransfected in 293T cells, with Flagtagged and Myc-tagged WT constructs used as positive controls. The A181E hTACI and A144E mTACI mutants assembled with their WT counterparts, although less efficiently than WT TACI with itself (see Fig E2, A and B, in this article's Online Repository at www.jacionline.org). The assembly of the mutants with WT TACI is not unexpected, given that the extracellular CRD1 domain, which is critical for the preassociation of WT TACI, is intact in these mutants.
We previously showed that the hTACI A181E and mTACI A144E mutations severely impair ligand-induced activation of NF-kB in 293T cell transfectants. 13 Additional studies demonstrated that both A181E hTACI and A144E mTACI mutants strongly inhibited the ability of cotransfected WT TACI to (Fig 1, C) and tetanus toxoid (TT)-specific IgG (Fig 1, D) in sera from Swedish asymptomatic subjects carrying a heterozygous TACI A181E mutation (n 5 14) and healthy control subjects (n 5 20). Data are expressed as OD at 405 nm or international units per milliliter. Sera were used at 1:100 dilution in Fig 1, A (for IgM) , B, and D, and 1:500 dilution in Fig 1, A (for IgG). Columns or symbols and bars represent means 6 SEMs. *P < .05, **P < .01, and ***P < .001, Student t test. ns, Not significant. J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 4 activate NF-kB in 293 T cells (see Fig E2, C and D) . Furthermore, TACI-driven B-cell responses of TACI 1/2 mice that carry an mTACI A144E-expressing transgene were intermediate between those of TACI 2/2 and TACI 1/2 mice. 13 These results indicate that the mutants, when overexpressed, can act as dominantnegative mutations. However, overexpression systems are not physiologic. To definitively address the effect of the heterozygous A144E mutation on B-cell function, we generated gene-targeted knock-in mice that carry a Tnfrsf13b allele that encodes the TACI A144E mutant in the endogenous locus, mimicking human subjects heterozygous for the A181E TACI mutation (see Fig E1) .
Homozygous TACI A144E/A144E mice, heterozygous TACI
1/A144E
mice and WT TACI 1/1 littermates, as well as TACI 1/2 and TACI 2/2 mice, were bred for more than 10 generations on the C57BL/6 background. None of the mutants differed in growth, weight, or health from their WT littermates, and all had normal lymphocyte cellularity in the thymus, bone marrow, and spleen (data not shown). B-cell development in the bone marrow, T-and B-cell distribution in the spleen, and B-cell subsets in the spleen and peritoneal cavity were comparable in all 5 strains, with the exception, as previously reported, 5 (Fig 2, A) . Fluorescenceactivated cell sorting analysis revealed that the intensity of TACI expression on B cells was markedly diminished in TACI A144E/A144E mice and was approximately half normal in TACI 1/A144E and TACI 1/2 mice (Fig 2, B and C B and C, Representative fluorescence-activated cell sorting analysis (Fig 2, B) and pooled data (Fig 2, C) of the mean fluorescence intensity (MFI) of TACI surface expression on gated B220 1 splenic B cells.
D and E, Representative fluorescence-activated cell sorting analysis (Fig 2, D) and pooled data (Fig 2, E) of intracellular TACI expression in gated B220 1 peripheral B cells. MFI data presented are the net value of TACI expression (MFI of TACI minus MFI of isotype control). Columns and bars in Fig 2, A, C , and E, represent means 6 SEMs (n 5 3-5 mice per group). *P < .05, **P < .01, and ***P < .001, Student t test. n.d., Not detected.
expressed and demonstrate that the heterozygous A144E mutation results in haploinsufficiency.
TACI 1/A144E mice exhibit functional TACI haploinsufficiency in vitro B-cell proliferation to APRIL and IgG 1 secretion in response to APRIL plus IL-4 were significantly and comparably reduced in TACI 1/A144E and TACI 1/2 mice relative to those seen in WT control mice (Fig 3, A and B) . B cells from TACI A144E/A144E and TACI 2/2 mice did not respond to APRIL stimulation. There was no evidence of increased apoptosis or cell death in APRIL plus IL-4-stimulated cultures of B cells from TACI mutant mice compared with WT control mice, as determined by using Annexin V and propidium iodide staining (data not shown). B cells from all 5 strains of mice proliferated and secreted IgG 1 comparably in response to anti-CD40 plus IL-4 (Fig 3, A and  B) . These results indicate that the heterozygous TACI A144E mutation impairs TACI function in B cells in vitro.
TACI
1/A144E mice have impaired antibody response to TNP-Ficoll but normal antibody response to TD antigen TACI 2/2 mice have decreased serum immunoglobulin levels. 9, 13, 22 Serum IgM, IgG, and IgA levels were comparable in TACI 1/A144E mice, TACI 1/2 mice, and TACI 1/1 control mice (Fig 4, A) . Serum IgM, IgG, and IgA levels were significantly lower in TACI A144E/A144E mice compared with those in (Fig 4, B) .
9 TACI 1/A144E mice, like TACI 1/2 mice, had significantly and comparably lower IgM and IgG anti-TNP responses to TNP-Ficoll than TACI 1/1 control mice (Fig 4, B) . The antibody responses to TNP-Ficoll of TACI A144E/A144E mice were significantly lower than those of TACI 1/A144E and TACI 1/2 mice, and although they were higher than those of TACI 2/2 mice, the difference was not significant. These results indicate that the heterozygous TACI A144E mutation impairs the B-cell response to type II TI antigen in vivo.
The anti-TNP antibody response to trinitrophenylkeyhole limpet hemocyanin (TNP-KLH) in TACI 1/A144E , TACI A144E/A144E TACI
1/2
, and TACI 2/2 mice was comparable with that in WT control mice when measured on day 28 after immunization (data not shown), which is consistent with the previously reported normal response of TACI 2/2 mice to TNP-KLH. 22 It was recently reported that TACI 2/2 mice do not sustain the anti-NP IgG antibody response to the TD antigen NP-OVA. 14 We observed no significant decrease in levels of IgG anti-NP antibodies on days 35 and 56 after immunization with OVA-NP in any of the mutant strains compared with WT controls (Fig 4, C) . The normal response of TACI 1/A144E mice to TD antigens indicates that the mutant does not exert nonspecific effects on B-cell differentiation into antibody-producing cells.
TACI 1/A144E mice have decreased levels of natural antibodies to phosphocholine and increased susceptibility to pneumococcal inhalation challenge Antibodies to phosphocholine protect unimmunized mice from death after pneumococcal challenge. 23 Serum levels of natural IgM and IgG antibodies to phosphocholine were readily detected in TACI 1/1 mice but were virtually absent in TACI 2/2 mice, indicating that this response is largely TACI dependent (Fig 5,  A) . Serum levels of natural IgM and IgG antibodies to phosphocholine were significantly lower in TACI 1/A144E and TACI 1/2 mice compared with those in TACI 1/1 control mice (Fig 5, A) . These results demonstrate that the heterozygous A144E mutation impairs the natural antibody response to phosphocholine.
We next examined the effect of the heterozygous A144E mutation on the response of unimmunized mice to pneumococcus. Analysis of Kaplan-Meier survival curves after intranasal challenge of unimmunized, pneumococcus-naive mice with S pneumoniae serotype 3 revealed that 78% (18/23) of TACI 1/1 mice survived 10 days after challenge (Fig 5, B) . In contrast, none of 12 TACI 2/2 mice survived the challenge, indicating that protection of naive mice against death from intranasal pneumococcal challenge is largely TACI dependent. The survival rates of TACI 1/A144E heterozygous mice (33% [4/12] of mice) and TACI 1/2 mice (38% [5/13] of mice) on day 10 after challenge were significantly lower than that of TACI 1/1 control mice but did not significantly differ from each other (Fig 5, B) . These results demonstrate that the heterozygous A144E mutation increases the susceptibility of naive mice to death after intranasal pneumococcal challenge.
DISCUSSION
We show that levels of natural antibodies to phosphocholine, which are implicated in resistance to pneumococcal infection, are significantly lower in reportedly healthy TACI A181E heterozygous adults and that mice heterozygous for TACI A144E, the murine counterpart to A181E, demonstrate increased susceptibility to pneumococcal infection. These results suggest that heterozygosity for the TACI A181E mutation might confer an increased risk for pneumococcal infections.
We identified reportedly healthy adult Swedish blood donors who were heterozygous for the TACI A181E mutation, which is consistent with the observation that relatives of patients with CVID who also carry the A181E mutation can be clinically healthy. 24 Blood donors heterozygous for the TACI A181E mutation had significantly lower levels of natural IgM and IgG antibodies to phosphocholine compared with TACI-sufficient control subjects. However, the affinity of IgG antibodies to phosphocholine was significantly increased in the A181E carriers compared with control donors. It was previously reported that the affinity of IgG antibodies to TD antigens is higher in TACI 2/2 mice compared with WT control mice.
14 Ligation of highaffinity B-cell receptors by antigen delivers an apoptotic signal. 25 TACI has also been reported to deliver an apoptotic signal to B cells, whereas BAFF receptor, which shares common ligands with TACI, delivers a survival signal. 5, [26] [27] [28] Decreased TACI signaling, increased BAFF receptor signaling, or both might allow better survival of B cells that express high-affinity B-cell receptors, resulting in the production of higher-affinity antibodies. It would be of interest to study the postvaccination antibody Symbols and bars in Fig 5, A, indicate means 6 SEMs, and symbols in Fig 5, B , represent the percentage of surviving mice. *P < .05, **P < .01, and ***P < .001. Two-way ANOVA was used in Fig 5, A, and the log-rank (Mantel-Cox) test was used in Fig 5, B. response to pneumococcal polysaccharides in these apparently healthy carriers of the A181E mutation. However, this was not possible because all subjects were deidentified. TACI A181E carriers also had significantly lower levels of natural IgM antibodies to E coli antigens, raising the possibility that they might be susceptible to infections with organisms other than pneumococcus. The approximately 0.7% incidence of A181E heterozygosity in the cohort of Swedish blood donors we studied is more than 100-fold higher than the 1 in 25,000 estimated incidence of CVID in Sweden. Thus the majority of the A181E heterozygotes studied are unlikely to be closely related to patients with CVID, suggesting that their impaired natural antibody response is not caused by genes or factors associated with CVID. Our studies with TACI A144E knock-in mice clearly indicate that the TACI A144E mutant protein is poorly expressed in B cells. This is consistent with the location of this mutation at a predicted stability center of the protein. 29 Poor expression of the A144E mutant protein explains the observation that the level of TACI surface and intracellular protein in B cells of TACI 1/A144E heterozygous mice was about half that of WT B cells, which is comparable with that of B cells from TACI 1/2 mice. Thus the heterozygous A144E mutation results in haploinsufficiency of surface TACI expression in mouse B cells. TACI surface expression is reduced in B cells from patients with CVID and their asymptomatic relatives heterozygous for the A181E TACI mutation compared with that in normal control mice. 24 Mice heterozygous for the A144E TACI mutation displayed functional TACI haploinsufficiency. B-cell proliferation in response to APRIL stimulation, IgG 1 secretion in response to stimulation with APRIL plus IL-4, and, more importantly, antibody responses to the type II TI antigen TNP-Ficoll but not to the TD antigens NP-OVA and TNP-KLH were significantly reduced in heterozygous TACI 1/A144E mice and similar to those in haploinsufficient TACI 1/2 mice. Consistent with their poor expression of TACI, TACI A144E/A144E homozygous mice, such as TACI 2/2 mice, had markedly diminished TACI expression on B cells and a virtually absent response to APRIL in vitro. Unlike TACI 2/2 mice, TACI A144E/A144E mice had residual anti-TNP-Ficoll antibody responses and no expansion of splenic B cells, possibly suggesting the residual presence of some functionally relevant receptors in these mice.
We showed that TACI is critical for the production of natural IgM and IgG antibodies to phosphocholine in mice, as evidenced by the virtual absence of these antibodies in sera of TACI 2/2 mice. Although we did not examine the opsonic activity of sera from the mice for pneumococcal bacteria in vitro, we demonstrated that TACI is critical for the survival of unimmunized mice after pneumococcal intranasal challenge because all TACI 2/2 mice succumbed after challenge compared with 22% of WT control mice. Both the levels of IgM and IgG antibodies to phosphocholine and the fraction of mice that survived pneumococcal challenge were significantly and similarly reduced in TACI 1/A144E and TACI 1/2 mice compared with those in WT control mice. Thus TACI haploinsufficiency caused by the heterozygous A144E TACI mutation or loss of a TACI allele significantly increases the susceptibility of mice to pneumococcal disease.
According to the US Centers for Disease Control and Prevention, pneumococcal disease is an important health problem accounting for 400,000 hospitalizations per year in the United States and with a case fatality rate of 5% to 7% in the elderly (http://www.cdc.gov/vaccines/pubs/pinkbook/down loads/pneumo.pdf). Our findings in TACI 1/2 mice suggest that lack of expression of TACI encoded by a mutant TNFRSF13B allele in human subjects might impair their antibody response to pneumococcus and increase susceptibility to pneumococcal infection. Consistent with this hypothesis, patients with the Smith-Magenis syndrome, who have a chromosome 17p11.2 microdeletion that includes TNFRSF13B, have decreased TACI surface expression, a poor response to pneumococcus vaccination, and recurrent respiratory tract infections. 30 Although one needs to draw a cautious conclusion regarding human susceptibility to a given microorganism based on murine data, A181E carriers, such as the A144E knock-in mice, had significantly lower levels of natural antibodies to phosphocholine. Antibodies to phosphocholine, which is present on all S pneumoniae strains as part of the cell-wall polysaccharide, are thought to protect against invasive pneumococcal disease in human subjects. 19 Thus it is not far-fetched to propose that the increased susceptibility of A144E mice to S pneumoniae challenge is relevant to A181E carriers. It would be of interest to study over time whether healthy adults who carry the A181E mutation, including those related to patients with CVID with this mutation, are at increased susceptibility to pneumococcal infections and to examine healthy subjects who have had a pneumococcal infection for A181E heterozygosity.
Our results suggest that TACI A181E carriers, like TACI
1/A144E
mice, might be more susceptible to infection with pneumococcus and possibly other polysaccharide-encapsulated bacteria. Because TACI function is also disrupted in mice heterozygous for TACI C76R, the counterpart of the human TACI C104R mutation, 31 this mutation, like the A181E mutation, might also increase the risk of infection. This would have important implications for the approximately 1% of persons who carry one of these TACI mutations.
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Key messages
d TACI A181E heterozygosity in asymptomatic subjects is associated with decreased levels of natural antibodies to the pneumococcal polysaccharide phosphocholine and E coli antigens.
d Heterozygosity for mTACI A144E, which corresponds to hTACI A181E, results in TACI haploinsufficiency, with impaired production of natural antibodies to phosphocholine and increased susceptibility to pneumococcal infection.
METHODS TACI expression and coimmunoprecipitation in transfectants
293T cells were transfected with Myc-tagged WT hTACI or mTACI and either Flag-tagged WT hTACI, A181E hTACI, WT mTACI, or A144E mTACI by using FuGENE 6 (Roche, Mannheim, Germany). Forty-eight hours later, lysates were examined for expression and coimmunoprecipitation of Myc-tagged and Flag-tagged proteins, as previously described. (Fig E2, A) and WT and A144E mTACI in 293T cell transfectants (Fig E2, B) . C and D, NF-kB induction by APRIL in 293T cells transfected with WT hTACI, A181E hTACI or both (Fig E2, A) or with WT mTACI, A144E mTACI, or both (Fig E2, B) . Fold induction was calculated by dividing the normalized NF-kB luciferase result of APRIL-treated samples by the NF-kB luciferase result of untreated samples. Blots in Fig E2, A and B , are representative of 3 independent experiments. Results in Fig E2, C and D , represent means and SDs of 3 independent experiments. *P < .05 and ***P < .001, Student t test.
FIG E3.
Normal B-cell development in TACI A144E mice. B-cell subpopulations were examined in the bone marrow, spleen, and peritoneal cavity of 6-to 8-week-old TACI mice per group). *P < .05 and **P < .01.
